References

Advice

British national formulary (April 2013) [online; accessed 4 October 2013]

European Medicines Agency (2012) European public assessment report: Zoely [online; accessed 4 October 2013]

European Medicines Agency (2013) PRAC confirms that benefits of all combined hormonal contraceptives continue to outweigh risks [online; accessed 29 October 2013)

Faculty of Sexual and Reproductive Healthcare (2013) Faculty statement from the Clinical Effectiveness Unit: estradiol/nomegestrol combined pill, Zoely [online; accessed 7 October 2013]

Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit (2011) Clinical guidance: combined hormonal contraception [online; accessed 7 October 2013]

Gallo MF, Lopez LM, Grimes DA et al. (2011) Combination contraceptives: effects on weight. Cochrane Database of Systematic Reviews 2011, Issue 9: CD003987. DOI: 10.1002/14651858.CD003987.pub4

Mansour D, VerhoevenC, SommerW et al. (2011) Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen. The European Journal of Contraception and Reproductive Health Care 16: 430–43

Merck Sharp & Dohme Limited (2013) Zoely summary of product characteristics [online; accessed 4 October 2013]

Westhoff C, Kaunitz AM, Korver T et al. (2012) Efficacy, safety, and tolerability of a monophasic oral contraceptive containing nomegestrol Acetate and 17β-estradiol: a randomized controlled trial. Obstetrics & Gynecology 119: 989–99